Transforming Prostate Cancer Care: Innovations in Diagnosis, Treatment, and Future Directions

Author:

Vakili Sanaz1,Beheshti Iman1ORCID,Barzegar Behrooz Amir1ORCID,Łos Marek J.2ORCID,Vitorino Rui34ORCID,Ghavami Saeid1567ORCID

Affiliation:

1. Department of Human Anatomy and Cell Science, University of Manitoba College of Medicine, Winnipeg, MB R3E 3P5, Canada

2. Biotechnology Center, Silesian University of Technology, 44-100 Gliwice, Poland

3. Department of Medical Sciences, Institute of Biomedicine iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal

4. Department of Surgery and Physiology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal

5. Biology of Breathing Theme, Children Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB R3T 2N2, Canada

6. Faculty of Medicine, Akademia Śląska, Rolna 43, 40-555 Katowice, Poland

7. Paul Albrechtsen Research Institute, CancerCare Manitoba, University of Manitoba, Winnipeg, MB R3E 0V9, Canada

Abstract

Prostate cancer remains a major global health challenge, ranking as the second most common malignancy in men worldwide. Advances in diagnostic and therapeutic strategies have transformed its management, enhancing patient outcomes and quality of life. This review highlights recent breakthroughs in imaging, including multiparametric MRI and PSMA-PET, which have improved cancer detection and staging. Biomarker-based diagnostics, such as PHI and 4K Score, offer precise risk stratification, reducing unnecessary biopsies. Innovations in treatment, including robotic-assisted surgery, novel hormone therapies, immunotherapy, and PARP inhibitors, are redefining care for localized and advanced prostate cancer. Artificial intelligence (AI) and machine learning (ML) are emerging as powerful tools to optimize diagnostics, risk prediction, and treatment personalization. Additionally, advances in radiation therapy, such as IMRT and SBRT, provide targeted and effective options for high-risk patients. While these innovations have significantly improved survival and minimized overtreatment, challenges remain in optimizing therapy sequencing and addressing disparities in care. The integration of AI, theranostics, and gene-editing technologies holds immense promise for the future of prostate cancer management.

Funder

FCT—Fundação para a Ciência e Tecnologia, I.P.

Cardiovascular R&D Center

RISE

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3